Myeloma

Ryan Cohlhepp, from Takeda Oncology, discusses the accomplishments of the Moving Mountains for Multiple Myeloma team. Cohlhepp, along with other members of the team, were honored at our 2016 Multiple Myeloma Heroes event.

Jeff Goad and his wife, Ramona Biliunas, discuss why the climbed Mount Kilimanjaro as part of the Moving Mountains for Multiple Myeloma team. Jeff was also one of our 2016 Multiple Myeloma Heroes.

This is our full documentary from the 2016 climb of Mount Kilimanjaro.

Marlee Matlin, an Academy award-winning actress, discusses her father’s diagnosis and journey with multiple myeloma.

In keynote speech, TV and movie actress Marlee Matlin urges resilience.

Charles W. Wakefield attended the UCLA School of Dentistry and served in the U.S. Army Dental Corps. Currently, he is in private practice with his son in Lewisville, Texas.

The approval was based on results from a multicenter, open-label phase 2b study in which the overall response rate with Evomela was 95 percent among 61 patients.

Four new drugs, and novel treatment combinations, are further extending life expectancy for patients with multiple myeloma.

Multiple myeloma begins with a single precancerous plasma cell that multiplies uncontrollably and can eventually cause bone lesions and anemia.

A 15-person team of multiple myeloma patients, doctors, family members, and supporters climbed the renowned 19,341-foot Uhuru Peak on Mount Kilimanjaro in Tanzania, Africa, in January, to raise awareness and funds for critical multiple myeloma research.

After losing her husband to myeloma, Novis Durie continued his project, the International Myeloma Foundation, which now has more than 200,000 members in 140 countries.

In an interview with CURE, Craig Hofmeister provided insight into the potential for combination regimens in relapsed/refractory patients with multiple myeloma.

"There are not a whole lot of patients that are able to do something like this, so we were doing it for them as well," says Chuck Wakefield. "It meant so much to them to have their names on the banner."

In an interview with CURE, Philippe Moreau discusses the significance of Ninlaro's approval and the TOURMALINE-MM1 study.

The approval was based on findings from the phase 3 ENDEAVOR trial.